A new editorial paper titled “HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity” has been published in Oncotarget.
In this new editorial, researchers Marcus Schmidt, Hans-Anton Lehr, and Katrin Almstedt from the University Medical Center of Johannes Gutenberg University discuss HER2 in breast cancer. HER2 is a well-established prognostic and predictive factor in breast cancer, which is associated with a poor prognosis but also offers the chance of improved survival when treated with targeted therapies based on the monoclonal antibody trastuzumab, both in advanced (hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.71 to 0.94, P = 0.004) and in early (HR 0.66, 95% CI 0.57 to 0.77, P < 0.00001) stages.
The American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) defines HER2-positivity as either 3+ by immunohistochemistry (IHC) or 2+ with amplification by in situ hybridization (ISH). Yet, the vast majority of breast tumors are considered HER2- negative (IHC 0 or 1+ or 2+ without amplification) by these criteria, and it has until recently been accepted that HER2-negative tumors do not benefit from trastuzumab based therapy.
“Now, results of randomized trials with trastuzumab-based antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) have fundamentally challenged this long-held view,” state the researchers.
More information:
Marcus Schmidt et al, HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity, Oncotarget (2024). DOI: 10.18632/oncotarget.28598
Provided by
Impact Journals LLC
Citation:
Researchers discuss HER2-low and HER2-zero in breast cancer (2024, July 16)
retrieved 16 July 2024
from https://medicalxpress.com/news/2024-07-discuss-her2-breast-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
